DPP-4 inhibitor linagliptin ameliorates cardiovascular injury in salt-sensitive hypertensive rats independently of blood glucose and blood pressure

[1] Dzau VJ(2006)The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) Circulation 114 2850-2870

[2] Antman EM(2008)Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2545-2559

[3] Black HR(2008)10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577-1589

[4] Hayes DL(2013)Effect of strict glycemic control in patients with diabetes mellitus on frequency of macrovascular events Am J Cardiol 112 1033-1038

[5] Manson JE(2000)Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 405-412

[6] Plutzky J(2013)Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease Clin Sci (Lond) 124 17-26

[7] Popma JJ(2012)Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus Am J Cardiol 110 826-833

[8] Stevenson W(2012)Recent advances in incretin-based therapies Clin Endocrinol (Oxf) 77 489-499

[9] Gerstein HC(2013)An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease Atherosclerosis 226 305-314

[10] Miller ME(2013)Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats Endocrinology 154 2501-2513

[1] Dzau VJ(2006)The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease) Circulation 114 2850-2870

[2] Antman EM(2008)Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 358 2545-2559

[3] Black HR(2008)10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577-1589

[4] Hayes DL(2013)Effect of strict glycemic control in patients with diabetes mellitus on frequency of macrovascular events Am J Cardiol 112 1033-1038

[5] Manson JE(2000)Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study BMJ 321 405-412

[6] Plutzky J(2013)Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease Clin Sci (Lond) 124 17-26

[7] Popma JJ(2012)Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus Am J Cardiol 110 826-833

[8] Stevenson W(2012)Recent advances in incretin-based therapies Clin Endocrinol (Oxf) 77 489-499

[9] Gerstein HC(2013)An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease Atherosclerosis 226 305-314

[10] Miller ME(2013)Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats Endocrinology 154 2501-2513